Department of Physiology, Pomeranian Medical University, Szczecin, Poland.
Expert Opin Drug Discov. 2020 Jan;15(1):85-99. doi: 10.1080/17460441.2020.1682992. Epub 2019 Oct 29.
: Rheumatoid arthritis (RA) is an autoimmune disease that is characterized by chronic inflammation of the joints and affects 1% of the population. Polymorphisms of genes that encode proteins that primarily participate in inflammation may influence RA occurrence or become useful biomarkers for certain types of anti-rheumatic treatment.: The authors summarize the recent progress in our understanding of the genetics of RA. In the last few years, multiple variants of genes that are associated with RA risk have been identified. The development of new technologies and the detection of new potential therapeutic targets that contribute to novel drug discovery are also described.: There is still the need to search for new genes which may be a potential target for RA therapy. The challenge is to develop appropriate strategies for achieving insight into the molecular pathways involved in RA pathogenesis. Understanding the genetics, immunogenetics, epigenetics and immunology of RA could help to identify new targets for RA therapy. The development of new technologies has enabled the detection of a number of new genes, particularly genes associated with proinflammatory cytokines and chemokines, B- and T-cell activation pathways, signal transducers and transcriptional activators, which might be potential therapeutic targets in RA.
类风湿关节炎（RA）是一种自身免疫性疾病，其特征为关节慢性炎症，影响人群的 1%。编码主要参与炎症的蛋白质的基因多态性可能会影响 RA 的发生，或者成为某些类型抗风湿治疗的有用生物标志物。
作者总结了我们对 RA 遗传学认识的最新进展。在过去的几年中，已经确定了多个与 RA 风险相关的基因变体。还描述了新技术的发展以及有助于新药发现的新潜在治疗靶点的检测。
仍需要寻找新的基因，这些基因可能是 RA 治疗的潜在靶点。挑战在于制定适当的策略，以深入了解 RA 发病机制中涉及的分子途径。了解 RA 的遗传学、免疫遗传学、表观遗传学和免疫学可以帮助确定 RA 治疗的新靶点。新技术的发展使得能够检测到许多新的基因，特别是与促炎细胞因子和趋化因子、B 细胞和 T 细胞激活途径、信号转导物和转录激活物相关的基因，这些基因可能是 RA 的潜在治疗靶点。
